

Manufacturing and Marketing permission issued from SND Division from 01.01.2017 to till date.

S.No.	Drug Name	Indication	Date of Approval
1	Sofosbuvir 400 mg film coated Tablet	In combination with other medicinal products for the treatment of Chronic Hepatitis C (CHC) in adults	16.02.2017
2	Hydralazine tablets BP 25 mg (Additional Strength)	For moderate to severe hypertension (in conjunction with a β -adrenoceptor blocking agent or diuretic) and hypertensive crisis.	23.02.2017
3	Hydralazine tablets BP 50 mg (Additional Strength)	For moderate to severe hypertension (in conjunction with a β -adrenoceptor blocking agent or diuretic) and hypertensive crisis.	23.02.2017
4	Bendamustine hydrochloride injection 90 mg/mL (Fill volume 0.5 mL in 2 ml capacity vial & 2 mL filled in 2 mL capacity vial)	<ol style="list-style-type: none">1. For the treatment of patients with chronic lymphocytic leukemia2. For the use in Indolent B-cell Non-Hodgkin's Lymphoma (NHL) that has Progressed During or Within six months of treatment with Rituximab or a Rituximab containing Regimen.	02.03.2017
5	Eltrombopagolamine 25 mg/50 mg tablets (Additional indication)	For the treatment of thrombocytopenia in paediatric patients 1 year and older with chronic immune(idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. (It should be used only in patients with ITP whose degree of Thrombocytopenia and clinical condition increase the risk for bleeding. It should not be used in an attempt to normalize platelet counts).	02.03.2017